Showing results (91-100 of 3,348) with videos related to
Sort By:
Pageof 335
Pharmacoeconomics|September 10, 2003
Inhaled salmeterol/fluticasone propionate combination: a pharmacoeconomic review of its use in the management of asthmaKatherine A Lyseng-Williamson, Greg L PloskerPharmacoeconomics|June 17, 2003
Costs of bipolar disorderLeah Kleinman, Ana Lowin, Emuella Flood, et al.Pharmacoeconomics|May 31, 2002
New solutions for type 2 diabetes mellitus: the role of pioglitazoneLoren D GrossmanPharmacoeconomics|June 28, 2003
Determinants of drug costs in hopitalised patients with haemophilia: impact of recombinant activated factor VIIJean Philippe Galanaud, Nathalie Pelletier-Fleury, Hélène Logerot-Lebrun, et al.Pharmacoeconomics|November 26, 2019
Healthcare Expenditures for the Treatment of Patients Infected with Hepatitis C Virus in JapanHaruhisa Fukuda, Yoshihiko Yano, Daisuke Sato, et al.Pharmacoeconomics|December 11, 2019
Multi-criteria Decision Analysis Software in Healthcare Priority Setting: A Systematic ReviewAlexander Moreno-Calderón, Thai S Tong, Praveen ThokalaPharmacoeconomics|January 22, 2020
Correction to: The Cost Effectiveness of Genetic Testing for CYP2C19 Variants to Guide Thienopyridine Treatment in Patients with Acute Coronary SyndromesLaura Panattoni, Paul M Brown, Braden Te Ao, et al.Pharmacoeconomics|April 3, 2020
R and Shiny for Cost-Effectiveness Analyses: Why and When? A Hypothetical Case StudyRose Hart, Darren Burns, Bram Ramaekers, et al.Pharmacoeconomics|November 24, 2020
Use of Productivity Loss/Gain in Cost-Effectiveness Analyses for Drugs: A Systematic ReviewAkira Yuasa, Naohiro Yonemoto, Michael LoPresti, et al.Pharmacoeconomics|November 25, 2020
Comparing the Analysis and Results of a Modified Social Accounting Matrix Framework with Conventional Methods of Reporting Indirect Non-Medical CostsBaudouin Standaert, Christophe Sauboin, Quentin J Leclerc, et al.Pageof 335